Figure 2.

A-B Reconstitution of NK and effector T cells after allogeneic HSCT in three patients who developed GvHD. (A) NK cell dynamics. (B) Effector T-cell (CD45RO⁺ CD27⁻ and CD45RO⁻ CD27⁻) dynamics with CD4 and CD8 populations in the upper and lower panels, respectively. Mean and SEM are shown for patients who did not develop GvHD. Horizontal dotted lines enclosing gray boxes represent the median and inter-quartile range for 11 age-matched healthy volunteers. Patient 12: female with an HLA-matched unrelated male donor, who received donor lymphocyte infusions beginning day 228. Patient 14: female with an HLA-matched sibling male donor, who received donor lymphocyte infusions beginning day 321. Patient 25: male with an HLA-matched unrelated male donor. GvHD therapy regimens are indicated for each patient (aGvHD is acute GvHD, cGvHD is chronic GvHD, PUVA is psoralen ultra violet A).